1. Medtech Insight
  2. >>Business

First Test That Can Detect COVID-19 Virus Mutations Authorized By FDA

The US FDA on 10 June authorized use of Illumina’s COVIDSeq next generation sequencing diagnostic test to detect the SARS-CoV-2 virus and figure out if it’s mutating. The agency has high hopes this first-of-its-kind test will give researchers a better picture in the ongoing global fight against the COVID-19 pandemic.

Virus and mutations process 3d illustartion. New virus mutation of coronavirus, hantavirus, COVID-19, pandemic concept background for health, medical design. Coronavirus mutation 3d rendering.
The FDA is optimistic Illumina’s COVIDSeq NGS test can help researchers understand potential mutations of the SARS-COV-2 virus, as illustrated

Illumina Inc.'s COVIDSeq is the first next-generation sequencing (NGS) diagnostic test to be given emergency use authorization by the Food and Drug Administration. The head of the US agency says the test will allow physicians to diagnose whether a patient has the SARS-CoV-2 virus and let researchers track whether it’s mutating.

The FDA said on 10 June it had granted authorization for the COVIDSeq diagnostic test as the first of its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

Where Do Questions Surrounding The EU’s AI Act Leave The Medtech Industry?

 
• By Amanda Maxwell

The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.

HistoSonics’ Edison System Gains Limited UK Access, While Awaiting CE Marking

 
• By Shubham Singh

While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.

Medtech Giants Brace for Tariffs Impact: Responses Range From Financial To Philosophical

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.